Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3277 - Long Term Survival in Patients Responding to an Anti-PD-1/PD-L1 Therapy and Disease Outcome Upon Treatment Discontinuation


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Immunotherapy


Marie-Léa Gauci


Annals of Oncology (2017) 28 (suppl_5): v403-v427. 10.1093/annonc/mdx376


M. Gauci1, E. Lanoy2, S. Champiat3, J. Michot1, A. Varga1, R. Bahleda1, E. Angevin1, A. Gazzah1, L. Verlingue1, F. Bigot1, S. Aspeslagh1, E. Castanon1, C. Baldini1, S. Postel-Vinay1, C. Massard1, A. Hollebecque1, J. Soria1, A. Marabelle1

Author affiliations

  • 1 Drug Development Department (ditep), Gustave Roussy, 94805 - Villejuif/FR
  • 2 Biostatistiques Et Epidémiologie, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Inserm U981, Gustave Roussy, 94805 - Villejuif/FR


Abstract 3277


The long-term outcome of cancer patients responding to an anti-PD-1/PD-L1 immunotherapy (IT) remains unknown. This study aimed to describe the long-term survival of patients responding to anti-PD-1/PD-L1 monotherapy across multiple cancer types.


306 patients treated with an anti-PD-1 or PD-L1 monotherapy in a phase 1 trial at Gustave Roussy were retrospectively analyzed over a period of 5 years. Major inclusion criteria were: at least 18 years-old, performance status 0-1, at least 1 infusion, evaluation by RECIST 1:1 and/or irRC. Multiple myeloma patients were excluded as they do not respond to anti-PD-1 monotherapy. All other cancer types (n = 19) were included.


The overall objective response rate within this cohort of 262 patients was 29% (n = 76; 77% being evaluated by irRC). The median PFS of responders was 22 months and the median OS was not reached. The OS of patients responding to IT at 3 years was 76% and at 5 years was 63%. Long responders (patients with enough follow up to have tumor responses lasting more than 2 years) represented 11.8% of the cohort (31 patients). No death occurred in the 21 complete responders over this long term follow up. The median duration of response was not reached. Out of the 33 patients who disontinued immunotherapy, 9 patients showed a disease relapse (median response duration after treatment discontinuation: 6 months). Clinical and biological factors associated with response, long term survival, and secondary refractory disease will be reported at the ESMO meeting.


This study shows that, across cancer types, patients with objective tumor responses under anti-PD-1/PD-L1 immunotherapy have a high level of overall survival. Best survivals are seen with complete responses (no deaths in our cohort). Complete response rate might be a good short term surrogate marker for overall survival benefits. Clinical trials aiming at putting patients with partial responses under immunotherapy into complete responses should be assessed in a near future.

Clinical trial identification


Legal entity responsible for the study

Gustave Roussy




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.